Chinese drug makers’ licensing deals more than doubled in 2025 from a year earlier to a record high, propelled by dozens of multibillion-dollar agreements between Hong Kong and mainland China-listed firms and global pharmaceutical giants.
Last year, 157 out-licensing deals worth US$135.7 billion were signed, compared with 94 transactions worth US$51.9 billion in 2024, state media reported, citing data released by the National Medical Products Administration (NMPA), China’s drugs regulator, last…
Chinese drug makers strike a record US$136 billion in out-licensing deals in 2025
